PYPD vs. NEPH, IINN, AKLI, SSKN, PAVM, TTOO, FEMY, MHUA, NMTC, and GCTK
Should you be buying PolyPid stock or one of its competitors? The main competitors of PolyPid include Nephros (NEPH), Inspira Technologies Oxy B.H.N. (IINN), Akili (AKLI), STRATA Skin Sciences (SSKN), PAVmed (PAVM), T2 Biosystems (TTOO), Femasys (FEMY), Meihua International Medical Technologies (MHUA), NeuroOne Medical Technologies (NMTC), and GlucoTrack (GCTK). These companies are all part of the "surgical & medical instruments" industry.
PolyPid (NASDAQ:PYPD) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, valuation, profitability, risk, dividends, earnings and analyst recommendations.
26.5% of PolyPid shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Comparatively, 4.1% of Nephros shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
PolyPid has a net margin of 0.00% compared to Nephros' net margin of -11.06%. Nephros' return on equity of -18.25% beat PolyPid's return on equity.
In the previous week, Nephros had 1 more articles in the media than PolyPid. MarketBeat recorded 4 mentions for Nephros and 3 mentions for PolyPid. Nephros' average media sentiment score of 0.71 beat PolyPid's score of 0.00 indicating that Nephros is being referred to more favorably in the news media.
Nephros has higher revenue and earnings than PolyPid. Nephros is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.
PolyPid received 10 more outperform votes than Nephros when rated by MarketBeat users. Likewise, 72.41% of users gave PolyPid an outperform vote while only 39.29% of users gave Nephros an outperform vote.
PolyPid has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, Nephros has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500.
Summary
Nephros beats PolyPid on 8 of the 15 factors compared between the two stocks.
Get PolyPid News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYPD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
